Senti Biosciences (SNTI) is projected to report a Q2 2026 loss of $0.33 per share on revenue of approximately $0.015 million, with the stock trading near $0.45 against an average analyst price target of $13.50.
Investors are primarily focused on the clinical progress of SENTI-202 and the recently announced strategic transaction to spin off the company's lead assets into a private entity controlled by Celadon Partners.
This restructuring aims to address a critical cash runway deficit and a "going concern" warning disclosed in earlier 2026 filings by providing shareholders with contingent value rights.
Market participants will be looking for specific updates on the pivotal trial design for SENTI-202 in acute myeloid leukemia and the refined focus on the Regulator Dial platform.